StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) stock

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)

Close on Nov 17, 2026Market cap $3.73BP/E –Yield –

Tango Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Tango Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -229.9%. For fiscal 2025 it was -162.9%, against -309.7% the year before. The highest annual figure on record is -157.2% in fiscal 2021.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-162.9%+146.9
FY2024Dec 31, 2024-309.7%−31.2
FY2023Dec 31, 2023-278.5%+156.6
FY2022Dec 31, 2022-435.1%−277.9
FY2021Dec 31, 2021-157.2%+521.6
FY2020Dec 31, 2020-678.8%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2025Sep 30, 202529.5%+280.8
Q2 FY2025Jun 30, 2025-1221.4%−1092.8
Q1 FY2025Mar 31, 2025-739.5%−153.6
Q4 FY2024Dec 31, 2024-915.0%−348.6
Q3 FY2024Sep 30, 2024-251.3%−43.8
Q2 FY2024Jun 30, 2024-128.6%+13.3
Q1 FY2024Mar 31, 2024-585.9%−100.2
Q4 FY2023Dec 31, 2023-566.4%−113.2
Q3 FY2023Sep 30, 2023-207.4%+212.4
Q2 FY2023Jun 30, 2023-141.9%+288.9
Q1 FY2023Mar 31, 2023-485.7%−48.0
Q4 FY2022Dec 31, 2022-453.3%−67.6
Q3 FY2022Sep 30, 2022-419.8%−131.2
Q2 FY2022Jun 30, 2022-430.7%−406.0
Q1 FY2022Mar 31, 2022-437.8%−248.2
Q4 FY2021Dec 31, 2021-385.7%−288.7
Q3 FY2021Sep 30, 2021-288.6%–
Q2 FY2021Jun 30, 2021-24.8%–
Q1 FY2021Mar 31, 2021-189.6%–
Q4 FY2020Dec 31, 2020-97.0%–

More Tango Therapeutics figures

See a number that looks wrong?